Boston Scientific Repeatedly Honored as 'Annual Outstanding Innovative Enterprise', Advances Localization and Global Innovation in China

ShanghaiFebruary 23, 2023PR Newswire -- Today, at the 5th Global Business Leaders Forum hosted by the Economic Observer, Boston Scientific was awarded the "2022 Outstanding Innovation Enterprise." This award aims to identify and honor benchmark companies that focus on long-term innovation and help create an "open, shared, and innovation-driven" environment. Boston Scientific stood out with its innovative breakthroughs in local production and research, as well as its remarkable efforts in enhancing the accessibility of cutting-edge medical solutions, marking the second consecutive year the company has received this accolade.

Zhang Jun, President of Boston Scientific Greater China, said:“‘"Innovation" and "Localization" have always been the most prominent keywords for Boston Scientific in China.This consecutive win‘Enterprise of the Year for Outstanding Innovation’, is a testament to our commitment to staying at the forefront of medical advancements and maintaining our position over the long term.‘In Huawei Hua’Affirmation and encouragement for development. In the future, Boston Scientific will continue to cultivate this vibrant land of China with a sincere heart of ‘innovating for life’, join hands with partners from all sectors of the local ecosystem, and contribute to promoting high-quality development in the healthcare industry and safeguarding the health and well-being of the Chinese people.”

"2022 Annual Excellence in Innovation Enterprise" Trophy

Achieving a Milestone in Deep Localization Development through Accumulated Strength

As a witness and participant in the development of China's medical industry, Boston Scientific has always been exploring new models that resonate with the local ecosystem. The year 2022 can be considered as Boston Scientific's "Year of Localization" – Boston Scientific registered a new investment company to accelerate local integration in areas such as production, transformation, and innovation incubation; for the first time, it initiated a tender offer for a local company, further expanding its business layout in China while integrating global resources to help outstanding Chinese companies "go global."

Moreover, in the past year, Boston Scientific has made significant progress and achieved multiple breakthroughs in its local production and research field in China. Leveraging the Medical Device Registration Holder (MAH) system, Boston Scientific’s first product transitioning from "import to locally manufactured" – the Polaris Intravascular Ultrasound System.^[1]The approval in China has opened a new chapter for Boston Scientific's "Made in China, Serving the World"; exploring technology transfer with local enterprises, the first innovative device independently developed by a Chinese team ——"Rongyi" disposable radiofrequency ablation electrode ——has been successfully created.^[2]The localization of production has laid a milestone for Boston Scientific's localized production and research in China. These are innovative attempts by Boston Scientific to deepen its roots in China and enhance embedded development. It is hoped that with the successive launches of more innovative "locally produced products," it will better contribute to the upgrading and development of China's medical industry.

The First Chinese-Made Polaris Intravascular Ultrasound System Successfully Rolled Off the Production Line

"Rongyi" Single-Use Radiofrequency Ablation Electrode Completes First Surgery in China

Adhering to Integrity and Innovation, Accelerating the Benefits of Global Cutting-edge Achievements for Clinical Use

Continuously shortening the "time difference" for cutting-edge medical technologies to benefit Chinese patients and doctors is a goal that Boston Scientific strives for. Riding on the policy support from the Boao Lecheng Pilot Zone, in March 2022, the Rezūm (Rui Meng) Thermal Vapor Therapy Device and the disposable prostate thermal vapor therapy device were introduced.^[3]By leveraging "pilot programs" and "real-world studies" for rapid approval, it became the third case in the industry to successfully gain approval through the "Lecheng Express." Additionally, four global new products have also successively initiated "pilot program" surgeries, with the potential to accelerate the pace of benefiting patients in China.

While exploring the path to accelerate the introduction with Lecheng, Boston Scientific has also launched the "Lecheng 2.0" innovative collaboration to explore new models for enhancing the accessibility and affordability of high-quality medical services. For example, Boston Scientific innovatively promotes the TheraSphere Y-90 Glass Microspheres System.^[4]Included in the coverage scope of "Lecheng Special Drug Insurance," and subsequently also incorporated into local惠民insurance plans in Beijing, Suzhou, and Zhaoqing, significantly reducing the financial burden on patients and bringing new hope to more Chinese liver cancer patients.

Rezūm System Completes "Double Hundred Cases" of Clinical Treatment in China

First Case of Y90 Glass Microspheres "Pilot Trial" Surgery

Moreover, in the field of already marketed products, Boston Scientific continuously drives the accessibility of cutting-edge global innovations in China through technological advancements and collaborative innovation. Based on local clinical needs, Boston Scientific has developed digital tools such as the remote imaging support system MedLink and "Eagle Eye," which have pioneered a new model of remote teaching and clinical support that radiates from major centers to grassroots hospitals. Additionally, the "Thousand Counties Project for Precision PCI at the Grassroots Level" was launched to promote the widespread application of coronary intervention technology in county-level hospitals. In the future, Boston Scientific will continue to leverage its resource advantages and innovative heritage to empower local patients and healthcare providers, jointly building a sustainably healthy China.

[1] Registration Certificate No.: China Medical Device Registration 20223060932, China Medical Device Registration 20223060933
[2] Registration Certificate No.: Su Medical Device Registration Approval 20222010350
[3] Registration Certificate No.: China Medical Device Registration No. 20223090122, China Medical Device Registration No. 20223090123
[4] This product has not yet been launched in mainland China.

About Boston Scientific

Boston Scientific Corporation is committed to innovation for life. We are dedicated to innovative medical solutions that improve the lives of patients worldwide. For over four decades, Boston Scientific has consistently led the global medical technology industry by delivering a wide range of high-performance medical solutions that meet critical patient needs, reducing healthcare costs. For more detailed information, please visit the company's website:www.bostonscientific.cn

About Boston Scientific Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently has branches in Beijing, Guangzhou, Chengdu, Hong Kong, and Taipei. The company's core business areas cover cardiac intervention, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic intervention, peripheral and tumor intervention, urology, respiratory products, and more. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a medical technology company that meets the needs of doctors and patients, demonstrates innovative vitality, and commands respect by providing high-quality medical products and services for prevention, diagnosis, and treatment. For more detailed information, please visit the company website:www.bostonscientific.cn